This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding BeiGene's advancement of, and anticipated development and regulatory milestones and plans related to, BeiGene's drug candidates and clinical trials, including commencing registration and combination trials and providing data readouts and updates for its clinical and preclinical candidates.